Drug intelligence / Profile preview

RV-1730

Development stage: Unknown
Lead developer: RNAimmune
Modality: Small Molecules, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RV-1730 is an investigational mRNA-based vaccine developed by RNAimmune (a subsidiary of Sirnaomics) for use as a booster against COVID-19. It is designed to provide prophylactic protection against SARS-CoV-2 infection, including contemporary variants such as Omicron and XBB. The vaccine works by encoding antigens from the SARS-CoV-2 virus to stimulate an immune response that includes both B and T cell activation and durable neutralizing antibody production. As of early 2025, it has received FDA clearance for Phase 1 clinical trials in the United States to evaluate its safety and immunogenicity in adults previously vaccinated with other mRNA COVID-19 vaccines.

Other names: RV-1730RV1730RV 1730

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on RV-1730.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RV-1730.

Explore the full profile